Hyeajin Gil

HyeaJin Gil currently serves as Principal Scientist in CMC Analytical Development at Aurion Biotech since May 2024, following a similar role at Garuda Therapeutics from November 2022 to May 2024. Previous experience includes Senior Scientist at ActivSignal and Research Lab Specialist at St. Jude Children's Research Hospital, where significant contributions involved understanding tumorigenesis in Wilms tumor and the regulatory roles of WT1 and KDM6B. HyeaJin's postdoctoral research at Northwestern University focused on lymphatic vasculature development, with an earlier postdoctoral role at St. Jude continuing similar themes. Research expertise stems from a solid educational background, including a PhD in Biochemistry and Molecular Biology from Louisiana State University and a Master's in Molecular Genomic Medicine from Seoul National University. Recognized for work in cancer research and epigenetic regulation, HyeaJin has also contributed to studies on stem cell biology and chronic kidney disease models.